IV Daratumumab versus Subcutaneous Daratumumab

IV Daratumumab versus Subcutaneous Daratumumab

obr

5 months
115 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine, compares intravenous daratumumab versus subcutaneous daratumumab.
Up Next Autoplay
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
Category: Acute Lymphoblastic Leukemia
1 Views
Cancer-News 27 minutes
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
Category: Chronic Lymphocytic Leukemia
1 Views
Cancer-News 30 minutes
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Category: Non-Hodgkin Lymphoma
2 Views
Cancer-News 31 minutes
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
Category: News
1 Views
Cancer-News 35 minutes
Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019
Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019
Category: News
5 Views
Cancer-News 36 minutes
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
Category: Multiple Myeloma
1 Views
Cancer-News 39 minutes
FerGene Announces Pivotal Phase 3 Study of Nadofaragene Firadenovec Met Its Primary Endpoint With More Than Half of Patients With High-Grade Non-Muscle Invasive Bladder Cancer (CIS ± Ta/...
FerGene Announces Pivotal Phase 3 Study of Nadofaragene Firadenovec Met Its Primary Endpoint With More Than Half of Patients With High-Grade Non-Muscle Invasive Bladder Cancer (CIS ± Ta/...
Category: News
0 Views
Cancer-News 42 minutes
The Leukemia & Lymphoma Society (LLS) and The American Society of Hematology (ASH) Team Up to Connect Blood Cancer Patients to Clinical Trials that Can Lead to New and Better Treatments
The Leukemia & Lymphoma Society (LLS) and The American Society of Hematology (ASH) Team Up to Connect Blood Cancer Patients to Clinical Trials that Can Lead to New and Better Treatments
Category: News
0 Views
Cancer-News 43 minutes
ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies
ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies
Category: General
0 Views
Cancer-News 44 minutes
Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition
Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition
Category: News
0 Views
Cancer-News 47 minutes